Artificial Intelligence in Diagnosis and Prognosis of Cognitive Impairment in Parkinson's Disease.

IF 2.2 4区 医学 Q3 CLINICAL NEUROLOGY
Aysan Moeinafshar, Amir Reza Barati, Sahand Tehrani Fateh, Mohammad Taha Pahlevan Fallahy, Alireza Soltani Khaboushan
{"title":"Artificial Intelligence in Diagnosis and Prognosis of Cognitive Impairment in Parkinson's Disease.","authors":"Aysan Moeinafshar, Amir Reza Barati, Sahand Tehrani Fateh, Mohammad Taha Pahlevan Fallahy, Alireza Soltani Khaboushan","doi":"10.1159/000547180","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD), a progressive neurodegenerative disorder, affects millions globally, with cognitive impairment as a significant non-motor complication. These cognitive changes, ranging from mild cognitive impairment (MCI) to severe dementia, drastically reduce quality of life and worsen prognosis. Early and accurate detection is critical for effective management and therapeutic interventions. Recent advancements in artificial intelligence (AI) offer novel solutions for diagnosing, predicting, and managing cognitive deficits in PD by integrating diverse data modalities, including neuroimaging, electrophysiology, kinetic markers, and laboratory biomarkers. Prominent AI techniques, such as support vector machines, random forests, and convolutional neural networks have demonstrated high accuracy in analyzing multimodal data for cognitive profile prediction. Additionally, AI supports the development of personalized treatment strategies, both pharmacological and non-pharmacological, and enhances accessibility through telemedicine initiatives. Despite these advancements, challenges persist in standardizing methodologies, improving model interpretability, and integrating AI tools into clinical practice. Overcoming these hurdles will require robust validation studies and multidisciplinary collaboration. This review examines the transformative role of AI in analyzing multimodal datasets to classify cognitive impairments, predict disease progression, and identify therapeutic targets, paving the way for personalized, patient-centered care in PD management.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-44"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547180","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson's disease (PD), a progressive neurodegenerative disorder, affects millions globally, with cognitive impairment as a significant non-motor complication. These cognitive changes, ranging from mild cognitive impairment (MCI) to severe dementia, drastically reduce quality of life and worsen prognosis. Early and accurate detection is critical for effective management and therapeutic interventions. Recent advancements in artificial intelligence (AI) offer novel solutions for diagnosing, predicting, and managing cognitive deficits in PD by integrating diverse data modalities, including neuroimaging, electrophysiology, kinetic markers, and laboratory biomarkers. Prominent AI techniques, such as support vector machines, random forests, and convolutional neural networks have demonstrated high accuracy in analyzing multimodal data for cognitive profile prediction. Additionally, AI supports the development of personalized treatment strategies, both pharmacological and non-pharmacological, and enhances accessibility through telemedicine initiatives. Despite these advancements, challenges persist in standardizing methodologies, improving model interpretability, and integrating AI tools into clinical practice. Overcoming these hurdles will require robust validation studies and multidisciplinary collaboration. This review examines the transformative role of AI in analyzing multimodal datasets to classify cognitive impairments, predict disease progression, and identify therapeutic targets, paving the way for personalized, patient-centered care in PD management.

人工智能在帕金森病认知功能障碍诊断和预后中的应用。
帕金森病(PD)是一种进行性神经退行性疾病,影响全球数百万人,认知障碍是一种重要的非运动并发症。这些认知变化,从轻度认知障碍(MCI)到严重痴呆,大大降低了生活质量并使预后恶化。早期和准确的检测对于有效的管理和治疗干预至关重要。人工智能(AI)的最新进展通过整合各种数据模式,包括神经成像、电生理学、动力学标记和实验室生物标记,为PD的诊断、预测和管理认知缺陷提供了新的解决方案。杰出的人工智能技术,如支持向量机、随机森林和卷积神经网络,在分析多模态数据用于认知轮廓预测方面已经证明了很高的准确性。此外,人工智能支持开发个性化治疗策略,包括药物和非药物治疗策略,并通过远程医疗举措提高可及性。尽管取得了这些进步,但在方法标准化、提高模型可解释性以及将人工智能工具整合到临床实践中仍然存在挑战。克服这些障碍需要强有力的验证研究和多学科合作。本综述探讨了人工智能在分析多模态数据集以分类认知障碍、预测疾病进展和确定治疗靶点方面的变革作用,为PD管理中个性化、以患者为中心的护理铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
0.00%
发文量
46
审稿时长
2 months
期刊介绍: As a unique forum devoted exclusively to the study of cognitive dysfunction, ''Dementia and Geriatric Cognitive Disorders'' concentrates on Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信